Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

被引：2
|
作者：
Shahid, Zainab [1 ,2 ]
Okwali, Michelle [3 ]
Joseph, Ashlee [4 ]
Seo, Susan K. [2 ,5 ]
Lue, Jennifer Kimberly [4 ]
Boardman, Alexander P. [3 ]
Caron, Philip [3 ]
David, Kevin A. [3 ]
Epstein-Peterson, Zachary D. [3 ]
Ghione, Paola [4 ]
Hamlin, Paul A. [3 ]
Horwitz, Steven M. [4 ]
Intlekofer, Andrew M. [3 ]
Johnson, William [4 ]
Kumar, Anita [6 ]
Moskowitz, Alison [4 ]
Noy, Ariela [3 ]
Owens, Colette [3 ]
Palomba, Maria Lia [3 ]
Stuver, Robert [4 ]
Torka, Pallawi [3 ]
Vardhana, Santosha A. [3 ]
Zelenetz, Andrew D. [3 ]
Salles, Gilles [3 ]
Falchi, Lorenzo [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, New York, NY USA
[2] Weill Cornell Med, Dept Med, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, Short Hills, NJ USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187911
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)
    Narkhede, Mayur
    Bartlett, Nancy L.
    Ibrahimi, Sami
    Popplewell, Leslie
    Seto, Anna
    Bates, Jamie
    Lee, Yeonju
    Ganti, Vaishnavi
    Han, Ling
    Chen, Tianling
    Patel, Manish R.
    EJHAEM, 2023, 4 (02): : 370 - 380
  • [42] MBS303, a Novel 2:1 CD20xCD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I , Dose-Escalation Trial
    Song, Yuqin
    Yang, Haiyan
    Jia, Youchao
    Sheng, Lixia
    Deng, Lijuan
    Chen, Xi
    Tang, Yongjing
    Liu, Xifang
    Liu, Sijun
    Wei, Min
    Li, Feng
    BLOOD, 2024, 144 : 6481 - 6482
  • [43] Liposomal encapsulated daunorubicin (DaunoXome(R)) has activity in relapsed/refractory low grade and intermediate grade non-Hodgkin's lymphoma (NHL).
    Tulpule, A
    Rarick, MU
    Kolitz, J
    Bernstein, J
    Traynor, A
    Myers, A
    HarveyBuchanan, L
    Salvosa, MVD
    Espina, BM
    Mukwaya, G
    Ross, M
    Levine, AM
    BLOOD, 1996, 88 (10) : 358 - 358
  • [44] A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    Kim, Tae Min
    Alonso, Arancha
    Prince, Miles
    Taszner, Michal
    Cho, Seok-Goo
    Stevens, Don A.
    Poon, Michelle
    Lim, Francesca
    Le Gouill, Steven
    Carpio, Cecilia
    Keating, Mary-Margaret
    Adriaens, Lieve
    Ufkin, Melanie
    Sabir, Ayesha
    Li, Jingjin
    Jankovic, Vladimir
    Zhu, Min
    Brouwer-Visser, Jurriaan
    Leng, Siyang
    Sirulnik, L. Andres
    Chaudhry, Aafia
    Ambati, Srikanth R.
    Seog, Kim Won
    BLOOD, 2020, 136
  • [45] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
  • [46] A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
    Larson, Sarah M.
    Chen, Yvonne Y.
    Johnston, Jim
    Roy, Sylvain
    Patel, Pinakin
    Benjamin, Jonathan E.
    BLOOD, 2023, 142
  • [47] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed Refractory Indolent Non-Hodgkin's Lymphoma (NHL).
    Dutia, Mrinal
    DeRoock, Ian
    Chee, Karen
    O'donnell, Robert
    Quirch, Christine
    Reed-Pease, Christine
    Tuscano, Joseph
    BLOOD, 2009, 114 (22) : 670 - 670
  • [48] Anti-CD20 monoclonal antibody (rituximab) associated to mine and autotransplantation in patients with relapsed or primary refractary follicular or transformed follicular non-Hodgkin lymphoma (NHL).
    Solano, C
    Gutiérrez, AM
    Benet, I
    Marugán, I
    Tormo, M
    Terol, MJ
    Prósper, F
    García-Conde, J
    BLOOD, 1999, 94 (10) : 406B - 406B
  • [49] A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Shouse, Geoffrey P.
    Blum, Kristie A.
    Haydu, Julie E.
    Abramson, Jeremy S.
    Narkhede, Mayur
    Ip, Andrew
    Michaelson, Jennifer S.
    Baeuerle, Patrick A.
    Meetze, Kristan
    Shapiro, Irina
    Shearer, Todd
    Inumerable, Judith
    Jones, Jeff
    Awan, Farrukh T.
    BLOOD, 2023, 142
  • [50] A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
    Patel, Krish
    Riedell, Peter A.
    Tilly, Herve
    Ahmed, Sairah
    Michot, Jean-Marie
    Ghesquieres, Herve
    de Collela, Jean Marc Schiano
    Chanan-Khan, Asher
    Bouabdallah, Kamal
    Tessoulin, Benoit
    Iyengar, Sunil
    Long, Meixiao
    Clynes, Raphael
    Kanodia, Jitendra
    Bao, Lei
    Ding, Ying
    Jin, Jianhua
    Ainsworth, William B.
    Garcha, Raman
    Kye, Steve
    Phillips, Tycel J.
    BLOOD, 2022, 140 : 9470 - 9472
12345